Neuroendocrine Tumor – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of neuroendocrine tumors (NETs) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of NETs for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
Clarivate Epidemiology’s NETs forecast will answer the following question:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of NETs over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts the following NET patient populations:
- Diagnosed incident cases of NETs.
- Diagnosed incident cases of lung NETs.
- Diagnosed incident cases of gastroenteropancreatic NETs (GEP-NETs).
- Diagnosed prevalent cases of NETs.
- Diagnosed prevalent cases of lung NETs.
- Diagnosed prevalent cases of GEP-NETs.
- Diagnosed incident cases of nonmetastatic NETs.
- Diagnosed incident cases of metastatic NETs.
- … and many more (details available on request).
Note: Coverage may vary by country.
Table of contents
Harinder Kumar, B.D.S., M.P.H., is an associate epidemiologist at Clarivate. His areas of interest are cancer and psychiatric epidemiology. Previously, Dr. Kumar worked with the government of Punjab, National Health Mission, India. He received his M.P.H. from the Tata Institute of Social Sciences in Mumbai. He holds a B.D.S. in dentistry from the National Dental College and Hospital in Punjab.
Alexandre Vo Dupuy, M.Sc., Pharm.D., is a principal epidemiologist at Clarivate. Previously, he worked in the fields of consulting and real-world evidence and at a major pharmaceutical company. He obtained his doctor of pharmacy from Descartes University in Paris and his master’s degree in pharmacoepidemiology from the University of Bordeaux. He has worked in multiple therapy areas, with a focus on cancer epidemiology. He also codeveloped a scenario-based forecast for COVID-19.